Ardelyx Inc

Ardelyx CEO’s strategic 10 b‑5‑1 trades show confidence and long‑term alignment—buy low, sell wisely—offering investors insight into future growth plans.

Insider Mott David M buys 333k Ardelyx shares at $5.84, signalling confidence amid volatility and a potential catalyst for upside if clinical milestones hit.

Ardelyx insider buy by Chief Patient Officer Laura Williams shows confidence amid social‑media buzz and a bullish pipeline for IBSRELA and XPHOZAH, yet option sales signal risk‑aware management.